- Dr. Fauci publicly stated the lack of efficacy of hydroxychloroquine (HCQ) during a May 27 CNN interview, despite the subsequent retraction of the Lancet Surgisphere study.
- The medical establishment, including Dr. Fauci, did not investigate the fraud nor apologize for misleading information regarding HCQ, maintaining their stance against its use.
- The mainstream media largely ignored the retraction of the studies, continuing to propagate narratives blaming HCQ for patient deaths.
- Despite the FDA’s withdrawal of the Emergency Use Authorization for HCQ, many front-line doctors reported benefits when prescribing it appropriately.
- In March, Dr. Fauci controversially mandated that HCQ should only be used in clinical trials, overruling the medical judgment of treating physicians.
- Dr. Fauci’s claims on HCQ effectiveness were based on trials that excluded early treatment, which could have benefited patients during critical early infection stages.
- A study published by Henry Ford Health System on July 2 found HCQ reduced death rates even in mid-to-late COVID cases, prompting Dr. Fauci to criticize its findings.
- The FDA’s revocation of the EUA and Dr. Fauci’s response helped state governors restrict HCQ prescribing, contributing to high death rates in certain states like New York and Nevada due to limiting its use to hospitalized patients.
- On June 15, 2020, multiple state pharmacy boards and hospitals halted the dispensing and treatment of Hydroxychloroquine (HCQ).
- The NIAID stopped a clinical trial for HCQ due to low enrollment, and the FDA restricted access to donated HCQ doses.
- Sanofi ceased supplying HCQ for COVID treatment, and the WHO, influenced by major funders like Bill Gates, called for a halt to HCQ trials globally, leading to bans in several countries.
- Switzerland experienced a spike in COVID deaths after banning HCQ, which decreased upon its reintroduction, showcasing a significant correlation between HCQ availability and COVID-19 mortality.
- Nations that widely used HCQ reported considerably lower mortality rates, with access patterns revealing disparities between the U.S. and countries with accessible HCQ.
- An AAPS court filing indicated that countries like the Philippines and Poland had greater HCQ access and better health outcomes compared to the U.S.
- Studies indicated that nations with HCQ access faced 80% lower death rates and reviews affirmed its efficacy in reducing COVID mortality with negligible cardiac toxicity.
- Data from over sixty countries consistently showed a relationship between HCQ access and lower COVID-19 death rates.
- Poorer countries using hydroxychloroquine (HCQ) exhibited significantly lower case fatality rates from COVID-19 compared to wealthier nations that did not use HCQ.
- African countries like Senegal and Nigeria, despite predictions of high mortality rates, reported far fewer COVID fatalities than nations that restricted HCQ.
- Countries with lower hygiene standards, such as Ethiopia, Mozambique, Niger, Congo, and Ivory Coast, also showed better death rates compared to the United States.
- As of September 24, 2021, per capita death rates in the mentioned African nations ranged from 8 to 47.2 deaths per million, contrasted with over 200 deaths per million in western nations like Holland and the US.
- Dr. Meryl Nass noted that enhancing immune systems with zinc, vitamin C, and vitamin D could further reduce coronavirus deaths in malaria-prevalent regions.
- Countries such as Bangladesh, Senegal, Nigeria, and Turkey that permit unrestricted use of HCQ have significantly lower case fatality rates compared to wealthier democracies with strict HCQ protocols, including Ireland, Canada, and Belgium.
Recent Comments